General characteristics of the study population. Data are mean ± SD unless otherwise indicated.
| Variable | Data |
|---|---|
| F:M | 18:3 |
| Mean age, yrs | 60.9 ± 12.3 |
| Mean disease duration, yrs | 9.1 ± 6.8 |
| Previous prescriptions of bDMARD, % | 57.14 |
| ABA IV as first line bDMARD, % of cases | 42.86 |
| Previous ABA IV therapy duration, mos | 14.4 ± 8.4 |
| Concomitant csDMARD, % | 100 |
| DAS28 baseline | 3.32 ± 1.22 |
| DAS28 6 mos | 3.00 ± 0.89 |
bDMARD: biologic disease-modifying antirheumatic drug; ABA: abatacept; IV: intravenous; csDMARD: conventional synthetic DMARD; DAS28: 28-joint Disease Activity Score.